Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLNN NASDAQ:FHTX NASDAQ:RNAC NASDAQ:TKNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$6.27+0.3%$6.24$3.25▼$13.50$79.86M0.9272,157 shs33,703 shsFHTXFoghorn Therapeutics$5.95-1.0%$4.37$3.27▼$6.95$352.87M2.86356,242 shs293,937 shsRNACCartesian Therapeutics$9.46-2.2%$8.27$5.60▼$14.56$284.12M0.59296,698 shs133,007 shsTKNOAlpha Teknova$5.36-1.1%$4.65$1.91▼$6.68$290.59M0.62225,902 shs103,866 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene+0.32%+2.79%+14.00%+2.62%+63.71%FHTXFoghorn Therapeutics-1.00%+12.26%+54.55%+29.63%+7.99%RNACCartesian Therapeutics-2.17%-10.67%+27.32%+58.19%-31.30%TKNOAlpha Teknova-1.11%-7.43%+19.91%+90.07%+1.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLNNClene$6.27+0.3%$6.24$3.25▼$13.50$79.86M0.9272,157 shs33,703 shsFHTXFoghorn Therapeutics$5.95-1.0%$4.37$3.27▼$6.95$352.87M2.86356,242 shs293,937 shsRNACCartesian Therapeutics$9.46-2.2%$8.27$5.60▼$14.56$284.12M0.59296,698 shs133,007 shsTKNOAlpha Teknova$5.36-1.1%$4.65$1.91▼$6.68$290.59M0.62225,902 shs103,866 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLNNClene+0.32%+2.79%+14.00%+2.62%+63.71%FHTXFoghorn Therapeutics-1.00%+12.26%+54.55%+29.63%+7.99%RNACCartesian Therapeutics-2.17%-10.67%+27.32%+58.19%-31.30%TKNOAlpha Teknova-1.11%-7.43%+19.91%+90.07%+1.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLNNClene 2.71Moderate Buy$33.25430.30% UpsideFHTXFoghorn Therapeutics 2.88Moderate Buy$11.4392.08% UpsideRNACCartesian Therapeutics 2.43Hold$32.60244.61% UpsideTKNOAlpha Teknova 2.33Hold$8.0049.25% UpsideCurrent Analyst Ratings BreakdownLatest CLNN, FHTX, RNAC, and TKNO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/30/2026RNACCartesian Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell6/26/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/12/2026RNACCartesian Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/11/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/10/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.006/9/2026RNACCartesian Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$40.006/9/2026RNACCartesian Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$44.005/27/2026RNACCartesian Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$38.005/26/2026CLNNClene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/26/2026RNACCartesian Therapeutics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$42.00 ➝ $40.005/14/2026CLNNClene Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLNNClene$200K400.65N/AN/A($1.62) per share-3.87FHTXFoghorn Therapeutics$30.91M11.30N/AN/A($1.92) per share-3.10RNACCartesian Therapeutics$2.80M99.26N/AN/A($4.85) per share-1.95TKNOAlpha Teknova$40.52M7.09N/AN/A$1.28 per share4.19Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLNNClene-$26.17M-$3.20N/AN/AN/A-25,009.70%N/A-137.98%8/13/2026 (Estimated)FHTXFoghorn Therapeutics-$74.28M-$1.16N/AN/AN/A-266.88%N/A-35.38%8/4/2026 (Estimated)RNACCartesian Therapeutics-$130.30M-$5.90N/AN/AN/A-8,550.65%N/A-28.25%8/6/2026 (Estimated)TKNOAlpha Teknova-$17.26M-$0.32N/AN/AN/A-41.07%-24.32%-16.34%8/5/2026 (Estimated)Latest CLNN, FHTX, RNAC, and TKNO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026N/ARNACCartesian Therapeutics-$0.83N/AN/AN/A$0.18 millionN/A8/5/2026Q2 2026TKNOAlpha Teknova-$0.0833N/AN/AN/A$10.91 millionN/A8/4/2026Q2 2026FHTXFoghorn Therapeutics-$0.23N/AN/AN/A$7.05 millionN/A5/14/2026Q1 2026CLNNClene-$0.6367-$0.69-$0.0533-$0.69$0.05 million$0.02 million5/7/2026Q1 2026FHTXFoghorn Therapeutics-$0.28-$0.29-$0.01-$0.29$7.94 million$3.27 million5/6/2026Q1 2026TKNOAlpha Teknova-$0.0926-$0.08+$0.0126-$0.08$10.23 million$11.08 million4/30/2026Q1 2026RNACCartesian Therapeutics-$0.84-$1.46-$0.62-$1.46$0.22 million$0.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCLNNCleneN/AN/AN/AN/AN/AFHTXFoghorn TherapeuticsN/AN/AN/AN/AN/ARNACCartesian TherapeuticsN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLNNCleneN/A1.941.93FHTXFoghorn TherapeuticsN/A2.922.92RNACCartesian TherapeuticsN/A7.657.65TKNOAlpha Teknova0.204.593.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLNNClene23.28%FHTXFoghorn Therapeutics61.55%RNACCartesian Therapeutics86.95%TKNOAlpha Teknova13.81%Insider OwnershipCompanyInsider OwnershipCLNNClene28.30%FHTXFoghorn Therapeutics9.02%RNACCartesian Therapeutics37.20%TKNOAlpha Teknova12.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLNNClene10012.78 million9.16 millionNo DataFHTXFoghorn Therapeutics12058.71 million53.42 millionOptionableRNACCartesian Therapeutics6429.38 million18.45 millionOptionableTKNOAlpha Teknova24053.61 million46.91 millionNot OptionableCLNN, FHTX, RNAC, and TKNO HeadlinesRecent News About These CompaniesAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Arcus Biosciences (RCUS) and Tenaya Therapeutics (TNYA)June 4, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO) and REPRO-MED Systems (KRMD)May 9, 2026 | theglobeandmail.comAlpha Teknova, Inc. (NASDAQ:TKNO) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 9, 2026 | finance.yahoo.comAlpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comAlpha Teknova Charts Cautious Path to 2027 GrowthMay 7, 2026 | tipranks.comAlpha Teknova (TKNO) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comTeknova Reports First Quarter 2026 Financial ResultsMay 6, 2026 | globenewswire.comTeknova to Report First Quarter 2026 Financial Results on May 6, 2026April 22, 2026 | globenewswire.comFavourable Signals For Alpha Teknova: Numerous Insiders Acquired StockMarch 30, 2026 | finance.yahoo.comAlpha Teknova (NASDAQ:TKNO) CEO Acquires $55,900.00 in StockMarch 10, 2026 | insidertrades.comTeknova outlines 20%-25% long-term revenue growth target while investing $2M annually in commercial capabilitiesFebruary 27, 2026 | seekingalpha.comAlpha Teknova Inc (TKNO) Q4 2025 Earnings Call Highlights: Navigating Growth Amid ChallengesFebruary 27, 2026 | finance.yahoo.comAlpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call TranscriptFebruary 26, 2026 | seekingalpha.comTeknova Reports Fourth Quarter and Full Year 2025 Financial ResultsFebruary 26, 2026 | globenewswire.comEarnings To Watch: Alpha Teknova Inc (TKNO) Reports Q4 2025 ResultFebruary 25, 2026 | finance.yahoo.comAlpha Teknova (TKNO): Investors are Waiting for Leading Indicators to Drive SalesFebruary 20, 2026 | insidermonkey.comTeknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026February 5, 2026 | globenewswire.comWhy Alpha Teknova, Inc.’s (TKNO) Stock Is Down 13.01%December 22, 2025 | aaii.comAAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Voyager Therapeutics (VYGR) and Terns Pharmaceuticals (TERN)November 13, 2025 | theglobeandmail.comAlpha Teknova, Inc. (NASDAQ:TKNO) Analysts Are Pretty Bullish On The Stock After Recent ResultsNovember 8, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCLNN, FHTX, RNAC, and TKNO Company DescriptionsClene NASDAQ:CLNN$6.27 +0.02 (+0.32%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$6.20 -0.07 (-1.20%) As of 07/10/2026 05:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.Foghorn Therapeutics NASDAQ:FHTX$5.95 -0.06 (-1.00%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$5.94 0.00 (-0.08%) As of 07/10/2026 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Cartesian Therapeutics NASDAQ:RNAC$9.46 -0.21 (-2.17%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$9.48 +0.02 (+0.20%) As of 07/10/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.Alpha Teknova NASDAQ:TKNO$5.36 -0.06 (-1.11%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$5.36 +0.00 (+0.09%) As of 07/10/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab’s Stock Drop Comes With a Bullish Twist Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth PepsiCo’s Dividend Could Turn Patience Into Real Profit Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
